Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Everest Medicines Ltd. ( (HK:1952) ) just unveiled an announcement.
Everest Medicines Ltd. announced the grant of 1,237,374 options to Mr. Yifang Wu, an executive director and chairman of the board, under the Post-IPO Share Option Scheme. This move is part of the company’s strategy to align its remuneration policy with market standards and enhance operational efficiency. The options, which have no performance targets, are set to vest equally over four years and are expected to contribute to the company’s sustainable development and good corporate governance.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in the Greater China and Asian markets. The company specializes in innovative therapies for oncology, immunology, cardio-renal, and infectious diseases.
Average Trading Volume: 6,047,780
Technical Sentiment Signal: Buy
Current Market Cap: HK$20.15B
For a thorough assessment of 1952 stock, go to TipRanks’ Stock Analysis page.